ArticleScientific reports2017
Acute induction of anxiety in humans by delta-9-tetrahydrocannabinol related to amygdalar cannabinoid-1 (CB1) receptors.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Regular cannabis use is associated with altered activation of central executive and default mode networks even after prolonged abstinence in adolescent users: Results from a complementary meta-analysis.Neuroscience and biobehavioral reviews · 2019Pooled it
- Are cannabis-using and non-using patients different groups? Towards understanding the neurobiology of cannabis use in psychotic disorders.Journal of psychopharmacology (Oxford, England) · 2018Pooled it
- Dose-related reductions in prefrontal recruitment during cognitive reappraisal following oral delta-9-tetrahydrocannabinol in posttraumatic stress disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Trial
- Vaporized D-limonene selectively mitigates the acute anxiogenic effects of Δ9-tetrahydrocannabinol in healthy adults who intermittently use cannabis.Drug and alcohol dependence · 2024Trial
- A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.Translational psychiatry · 2020Trial
- Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults: a preliminary study.Psychopharmacology · 2020Trial
- Multimodal examination of the acute effects of cannabis on subjective and physiological stress-related outcomes: a randomized placebo-controlled laboratory study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Beyond cannabis use severity: associations of cannabis product type with sleep quality and mental health.Psychopharmacology · 2026Article
- Multimodal examination of daily stress rhythms in chronic Cannabis users.Psychopharmacology · 2026Article
- Cannabinoids and Extracellular Vesicles as Potential Biomarkers and Therapeutic Targets in Neuropsychiatric Disorders: A Hypothesis-Driven Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Cannabinoids for treating psychiatric disorders in youth: a systematic review of randomized controlled trials.Child and adolescent psychiatry and mental health · 2024Review
- Effects of cannabidiol, with and without ∆9-tetrahydrocannabinol, on anxiety-like behavior following alcohol withdrawal in mice.Frontiers in neuroscience · 2024Article
- PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.Molecular psychiatry · 2023Article
- Article
- PPARα and PPARγ are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice.Research square · 2023Article
- A critical review of cannabis in medicine and dentistry: A look back and the path forward.Clinical and experimental dental research · 2022Review
- Cannabinoids, reward processing, and psychosis.Psychopharmacology · 2022Review
- Biomarkers of the Endocannabinoid System in Substance Use Disorders.Biomolecules · 2022Review
- Shifting the Paradigm on Cannabis Safety.Cannabis and cannabinoid research · 2022Article
- Cannabinoid Receptor Type 1 Regulates Drug Reward Behavior via Glutamate Decarboxylase 67 Transcription.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
Use of Cannabis, the most widely used illicit drug worldwide, is associated with acute anxiety, and anxiety disorders following regular use. The precise neural and receptor basis of these effects have not been tested in man. Employing a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whether the effects of delta-9-tetrahydrocannabinol (delta-9-THC), the main psychoactive ingredient of cannabis, on anxiety and on amygdala response while processing fearful stimuli were related to local availability of its main central molecular target, cannabinoid-1 (CB1) receptors in man. Fourteen healthy males were studied with fMRI twice, one month apart, following an oral dose of either delta-9-THC (10 mg) or placebo, while they performed a fear-processing task. Baseline availability of the CB1 receptor was studied using PET with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.